Several inhibitors of the NLRP3 inflammasome have been reported to prevent tissue destruction in NLRP3-related allergic diseases in experimental models21, and our current data provide evidence that NLRP3 and caspase-1 are potential therapeutic targets for EoE. The gene discussed is NLRP3; the disease is allergic disease.